Datapoint: Independence Blue Cross to Launch Advanced Network for Gene Therapies

Philadelphia-based Blues affiliate Independence Blue Cross on Jan. 26 said it will launch an Advanced Network for Gene-Based Therapeutics in March of this year. The insurer is partnering with Penn Medicine and Children’s Hospital of Philadelphia in the creation of the new network, noting both providers “have played pivotal roles in the development and clinical trials of first-in-the-nation gene-based therapies.” While the network is intended to help Independence members access gene therapies, the press release noted that Luxturna and Zynteglo, both covered under Independence’s medical benefit, will “continue to require precertification.” Independence is currently the second-largest insurer in Pennsylvania, with 1,993,695 members.

Source: AIS’s Directory of Health Plans

0

0

0 Comments

0

0

• Datapoint